Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, prospective, noninterventional program analysing the safety and effectiveness of edoxaban

Next Previous
Trial Profile

A multicentre, prospective, noninterventional program analysing the safety and effectiveness of edoxaban

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms global ETNA-AF

Most Recent Events

  • 28 Aug 2023 Results assessing Persistence to edoxaban treatment in patients with atrial fibrillation using 2-year data from this study presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
  • 28 Aug 2023 Results (n=26,580 ) assessing clinical parameters associated with cardiovascular events in patients with AF receiving adequate anticoagulation presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
  • 28 Aug 2022 According to a Daiichi Sankyo media release, two-year effectiveness and safety outcomes in edoxaban-treated patients with and without a history of major bleeding, real-world effectiveness and safety of edoxaban in patients with and without a history of heart failure, and those with and without a history of ischaemic stroke from the program were presented at The European Society of Cardiology Congress 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top